Västra Hamnen Market Focus: CombiGene: New priorities after strategic decision
- Terminating the CG01 programme
- Implementing cost savings to prolong the financial runway
- Our fair value estimate is under review
Recently, CombiGene announced new priorities in its pipeline and a cost saving programme to prolong its financial runway. Peter Ekolind, the CEO, will comment in a live webcast hosted by Västra Hamnen Corporate Finance on Thursday October 31 at 3pm. After evaluating the prospects of the CG01 programme, including generated preclinical data, IP situation, capital requirements and likelihood of success, CombiGene decided to terminate the programme. The company will still be looking for a potential partner for CG01. CombiGene will now focus its R&D investments on the COZY programme for the treatment of chronic pain. Our fair value estimate is under review.
The full report is available here.